Hybrid closed-loop schemes have been shown to improve glucose control in comparison with insulin dosing entirely determined by the user [14] and have paved the way for the holy grail of T1D management, which is the development of fully closed-loop functionality or an artificial pancreas (AP) [15,16]. Here, INS is linked to type 1 diabetes mellitus.